Albert Hagelgans
Impact in
-
- Cancer, Lipids, and Metabolism
- Protease and Inhibitor Mechanisms
- Hematology top 10%
- Blood Coagulation and Thrombosis Mechanisms
Papers in
-
- Protein Kinase Regulation and GTPase Signaling 7
- Cancer-related gene regulation 2
- Epigenetics and DNA Methylation 2
- Histone Deacetylase Inhibitors Research 2
- PI3K/AKT/mTOR signaling in cancer 2
-
- Blood Coagulation and Thrombosis Mechanisms 5
- Co-authors
- Mario Menschikowski (23 shared papers)Gabriele Siegert (19 shared papers)Olga Sukocheva (6 shared papers)Maria Zamaraeva (2 shared papers)Andrey Y. Abramov (3 shared papers)Markus Friedemann (4 shared papers)Gjumrakch Aliev (1 shared paper)Elena Lukina (1 shared paper)
- Journals
- Thrombosis Research (2 papers)BMC Cancer (2 papers)Seminars in Cancer Biology (2 papers)Oncotarget (2 papers)Neoplasia (2 papers)
- Partner nations
- GermanyAustraliaUnited States
In The Last Decade
Albert Hagelgans
27 papers receiving 646 citations
Peers
Comparison fields: 5 of 82
- Cancer Research 107
- Hematology 74
- Internal Medicine 16
- Molecular Biology 341
- Immunology and Allergy 24
Countries citing papers authored by Albert Hagelgans
This map shows the geographic impact of Albert Hagelgans's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Hagelgans with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Hagelgans more than expected).
Fields of papers citing papers by Albert Hagelgans
This network shows the impact of papers produced by Albert Hagelgans. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Hagelgans. The network helps show where Albert Hagelgans may publish in the future.
Co-authors
The 25 scholars most cited alongside Albert Hagelgans, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 27 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2005 | 102 | |
| 2 | 2009 | 59 | |
| 3 | 2020 | 57 | |
| 4 | 2001 | 41 | |
| 5 | 1997 | 40 | |
| 6 | 2008 | 39 | |
| 7 | 2013 | 33 | |
| 8 | 2017 | 31 | |
| 9 | 2005 | 29 | |
| 10 | 2012 | 28 | |
| 11 | 2015 | 21 | |
| 12 | 2010 | 20 | |
| 13 | 2011 | 19 | |
| 14 | 2013 | 16 | |
| 15 | 2013 | 16 | |
| 16 | 2008 | 15 | |
| 17 | 2012 | 13 | |
| 18 | 2008 | 12 | |
| 19 | 2011 | 10 | |
| 20 | Silibinin down-regulates expression of secreted phospholipase A2 enzymes in cancer cells. | 2014 | 10 |
About Albert Hagelgans
Albert Hagelgans is a scholar working on Molecular Biology, Hematology, Pulmonary and Respiratory Medicine, Cancer Research and Genetics, having authored 27 papers that have together received 656 indexed citations. Recurring topics across this work include Protein Kinase Regulation and GTPase Signaling (7 papers), Blood Coagulation and Thrombosis Mechanisms (5 papers), Prostate Cancer Treatment and Research (3 papers), Protease and Inhibitor Mechanisms (2 papers), Cancer-related gene regulation (2 papers), Epigenetics and DNA Methylation (2 papers), Histone Deacetylase Inhibitors Research (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). The work is most often cited by research in Cancer Research (107 citations), Hematology (74 citations), Internal Medicine (16 citations), Molecular Biology (341 citations) and Immunology and Allergy (24 citations). Albert Hagelgans has collaborated with scholars based in Germany, Australia and United States. Frequent co-authors include Mario Menschikowski, Gabriele Siegert, Olga Sukocheva, Maria Zamaraeva, Andrey Y. Abramov, Markus Friedemann, Gjumrakch Aliev, Elena Lukina, Graeme Eisenhofer and Oliver Tiebel. Their work appears in journals such as Thrombosis Research, BMC Cancer, Seminars in Cancer Biology, Oncotarget and Neoplasia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.